Goldman Sachs
FOLD

Goldman Sachs’s Amicus Therapeutics FOLD Stock Holding History

Goldman Sachs’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,700
Closed -$432K – 6163
2020
Q4 		$432K Buy
+18,700
New +$382K ﹤0.01% 4692
2018
Q1 		– Sell
-250,000
Closed -$3.6M – 6051
2017
Q4 		$3.6M Sell
250,000
-252,200
-50% -$3.46M ﹤0.01% 3300
2017
Q3 		$7.57M Buy
+502,200
New +$6.64M ﹤0.01% 2795
2016
Q3 		– Sell
-46,800
Closed -$256K – 7065
2016
Q2 		$256K Sell
46,800
-98,600
-68% -$690K ﹤0.01% 5478
2016
Q1 		$1.23M Sell
145,400
-6,000
-4% -$42.5K ﹤0.01% 3916
2015
Q4 		$1.47M Buy
+151,400
New +$1.36M ﹤0.01% 3920
2015
Q3 		– Sell
-60,000
Closed -$849K – 7346
2015
Q2 		$849K Sell
60,000
-68,400
-53% -$822K ﹤0.01% 4684
2015
Q1 		$1.4M Buy
+128,400
New +$1.13M ﹤0.01% 4140
2014
Q4 		– Sell
-44,200
Closed -$263K – 7173
2014
Q3 		$263K Buy
+44,200
New +$232K ﹤0.01% 5886
2013
Q4 		– Sell
-44,100
Closed -$102K – 6692
2013
Q3 		$102K Hold
44,100
– – ﹤0.01% 6147
2013
Q2 		$103K Buy
+44,100
New +$136K ﹤0.01% 5864

Other funds holding FOLD

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Goldman Sachs's FOLD Position: Q2 2026 in Review

Goldman Sachs sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 11,556,008 shares — an estimated $167M sold.

Goldman Sachs first reported a position in FOLD in Q2 2013 and held it in 52 quarters. The position peaked at $167M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

  • Goldman Sachs reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 11,556,008 Amicus Therapeutics shares in Q2 2026, an estimated $167M.
  • Goldman Sachs first reported a position in Amicus Therapeutics in Q2 2013 and held it in 52 quarters.
  • Goldman Sachs's Amicus Therapeutics position peaked at $167M in Q1 2026.
  • 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.